Director Norden Gregory sold 33,500 shares of RPRX at $36.23 on 2025-08-11, reducing holdings by 14.7%
Norden Gregory, a director at Royalty Pharma plc, executed a sale of 33,500 shares at $36.23, reducing his shareholding from 228,348 to 194,848 shares—a decline of 14.7% in the batch sold. The transaction occurred at a price near the stock's 52-week high of $37.91 (currently $36.19), within a period of notable price momentum: +10.3% over 90 days and +1.0% over 30 days. The company's fundamentals show stable earnings (P/E of 13.76, net income of $30.2M on revenue of $578.7M), though annual revenue declined 3.9% year-over-year. This filing involves derivative securities conversion (Form 4 Table II), meaning the reported shares_after position does not represent total holdings; the insider's full position structure remains to be disclosed when derivative records populate.